{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:01:46Z","timestamp":1770436906006,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,4,9]],"date-time":"2011-04-09T00:00:00Z","timestamp":1302307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1637-5","type":"journal-article","created":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T12:53:03Z","timestamp":1302267183000},"page":"1439-1447","source":"Crossref","is-referenced-by-count":37,"title":["Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study"],"prefix":"10.1007","volume":"68","author":[{"given":"Ticiana B.","family":"Leal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot C.","family":"Remick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris H.","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Neuwirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"von Moltke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mulkerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,9]]},"reference":[{"key":"1637_CR1","first-page":"131","volume":"378","author":"AL Goldberg","year":"1997","unstructured":"Goldberg AL, Akopian TN, Kisselev AF et al (1997) New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem 378:131\u2013140","journal-title":"Biol Chem"},{"key":"1637_CR2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0959-440X(00)00075-0","volume":"10","author":"P Zwickl","year":"2000","unstructured":"Zwickl P, Baumeister W, Steven A (2000) Dis-assembly lines: the proteosome and related ATPase-assisted proteases. Curr Opin Struct Biol 10:242\u2013250","journal-title":"Curr Opin Struct Biol"},{"key":"1637_CR3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q","volume":"22","author":"A Ciechanover","year":"2000","unstructured":"Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22:442\u2013451","journal-title":"Bioessays"},{"key":"1637_CR4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0955-0674(97)80079-8","volume":"9","author":"A Hershko","year":"1997","unstructured":"Hershko A (1997) Roles of ubiquitin -mediated proteolysis in cell cycle control. Curr Opin Struct Biol 9:788\u2013799","journal-title":"Curr Opin Struct Biol"},{"key":"1637_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/bbrc.1998.8604","volume":"246","author":"T Oikawa","year":"1998","unstructured":"Oikawa T, Sasaki T, Nakamura M et al (1998) The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246:243\u2013248","journal-title":"Biochem Biophys Res Commun"},{"key":"1637_CR6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.274.5288.782","volume":"274","author":"AA Beg","year":"1996","unstructured":"Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782\u2013784","journal-title":"Science"},{"key":"1637_CR7","first-page":"215","volume":"4","author":"BR Zetter","year":"1993","unstructured":"Zetter BR (1993) Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:215\u2013218","journal-title":"Semin Cancer Biol"},{"key":"1637_CR8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","volume":"2","author":"MA Read","year":"1995","unstructured":"Read MA, Neish AS, Luscinskas FW et al (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493\u2013506","journal-title":"Immunity"},{"key":"1637_CR9","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"1637_CR10","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530\u20131534","journal-title":"Blood"},{"key":"1637_CR11","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557\u20133560","journal-title":"Blood"},{"key":"1637_CR12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"1637_CR13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS et al (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520\u2013525","journal-title":"Ann Oncol"},{"key":"1637_CR14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","volume":"22","author":"JF San-Miguel","year":"2008","unstructured":"San-Miguel JF, Richardson PG, Sonneveld P et al (2008) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22:842\u2013849","journal-title":"Leukemia"},{"key":"1637_CR15","doi-asserted-by":"crossref","first-page":"1727a","DOI":"10.1182\/blood.V112.11.1727.1727","volume":"112","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Richardson P, Schlag R et al (2008) A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 112:1727a","journal-title":"Blood"},{"key":"1637_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1637_CR17","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20134997","journal-title":"Blood"},{"key":"1637_CR18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"1637_CR19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115\u20131123","journal-title":"Br J Haematol"},{"key":"1637_CR20","unstructured":"Prepared by a Committee of the Chronic Leukemia\u2013Myeloma Task Force, National Cancer Institute (1968) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 3 1:17\u201339"},{"key":"1637_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS et al (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673\u2013683","journal-title":"Clin Chem"},{"key":"1637_CR22","doi-asserted-by":"crossref","first-page":"1008a","DOI":"10.1182\/blood.V108.11.1008.1008","volume":"108","author":"AK Stewart","year":"2006","unstructured":"Stewart AK, Sullivan D, Lonial S et al (2006) Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM). Blood 108:1008a","journal-title":"Blood"},{"key":"1637_CR23","unstructured":"Melamed J (2005) Repeat-dose pharmacokinetics and pharmacodynamics of bortezomib in patients with relapsed multiple myeloma. Report No. M34103-058 CSR. Millennium Pharmaceuticals, Inc., Cambridge"},{"key":"1637_CR24","doi-asserted-by":"crossref","first-page":"716a","DOI":"10.1182\/blood.V106.11.716.716","volume":"106","author":"AA Chanan-Khan","year":"2005","unstructured":"Chanan-Khan AA, Richardson P, Lonial S et al (2005) Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis. Blood 106:716a","journal-title":"Blood"},{"key":"1637_CR25","unstructured":"Ludwig H, Adam Z, Hajek R et al (2008) Bortezomib-doxorubicin-dexamethasone (BDD) for reversal of acute light chain induced renal failure (ARF) in multiple myeloma (MM). Results from a phase II study. Blood 112:Abstr 3682"},{"key":"1637_CR26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","volume":"33","author":"T Pekol","year":"2005","unstructured":"Pekol T, Daniels JS, Labutti J et al (2005) Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 33:771\u2013777","journal-title":"Drug Metab Dispos"},{"key":"1637_CR27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0959-8049(01)00358-6","volume":"38","author":"F Leger","year":"2002","unstructured":"Leger F, Seronie-Vivien S, Makdessi J et al (2002) Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur J Cancer 38:52\u201356","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1637-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1637-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T02:28:05Z","timestamp":1592447285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1637-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,9]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1637-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,9]]}}}